<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Gilead Sciences Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/gilead-sciences-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GILD) Gilead Sciences Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806</link>
		<comments>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806#comments</comments>
		<pubDate>Sun, 19 Feb 2012 03:43:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[STR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91806</guid>
		<description><![CDATA[We have maintained a Neutral rating on Gilead Sciences, Inc. (GILD) following appraisal of fourth quarter and full year 2011 results. Gilead’s adjusted earnings per share of 92 cents (including stock option expense) for the fourth quarter of 2011 missed the Zacks Consensus Estimate by 8 cents, as higher revenues were offset by increased research and development (R&#38;D) expenses. However, earnings were 2 cents above the year-earlier figure of 90 cents. Fourth quarter revenues were up 10% from the prior-year quarter to $2.2 billion, spurred by higher product sales. Total revenue also edged past the Zacks Consensus Estimate of $2.19 billion. Other than the fourth quarter miss, 2011 was an eventful year for Gilead on all fronts, namely commercial, regulatory and financial. Gilead’s strategy of creating fixed-dose combinations of existing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ILMN) Two Major Biotech Trends In 2012</title>
		<link>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438</link>
		<comments>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438#comments</comments>
		<pubDate>Thu, 19 Jan 2012 23:34:54 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90438</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood for the J.P. Morgan Healthcare Conference drank their fill of Patron, ate a few tons of filets and guzzled thousands of gallons of Starbucks coffee. What makes the conference such a big deal is that it’s the largest and most important investor event of the year in the healthcare sector. There are other healthcare conferences put on by investment banks, but nothing comes close to the quality and number of companies and attendees at JPM. There were two important takeaways that emerged from the conference – themes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals</title>
		<link>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883</link>
		<comments>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89883</guid>
		<description><![CDATA[The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&#38;A) deals have taken place in the pharma sector over the last couple of years. With most of the big pharma players already facing or likely to face generic threats to their key products, the companies are resorting to M&#38;As and in-licensing deals to counter the loss of revenues that will arise following the genericization of its key drugs. Pharma major Bristol-Myers is no exception as the generic threat looms over many of its key drugs, including the blockbuster blood-thinner Plavix, co-developed with Sanofi (SNY). Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions, and is introducing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Spotlight on Hepatitis-C Market</title>
		<link>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141</link>
		<comments>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88141</guid>
		<description><![CDATA[Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies &#8211; as evident by the deals being signed for the development of drugs for the treatment of HCV. We are talking about the recent announcements made by big players like Johnson &#38; Johnson (JNJ), Bristol-Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD). All three companies have made it clear they want a piece of the HCV market pie. Johnson &#38; Johnson’s Tibotec Pharmaceuticals and Bristol-Myers Squibb recently announced that they have decided to join forces for the development of Bristol-Myers’ daclatasvir (BMS-790052) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead&#8217;s Eviplera Drug is Cleared by European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725</link>
		<comments>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:44:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[STR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87725</guid>
		<description><![CDATA[Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed HIV drug Truvada (a fixed-dose, once-daily tablet containing Gilead&#8217;s Viread and Emtriva) and Johnson and Johnson’s (JNJ) new HIV drug Edurant. The STR is already marketed as Complera in the US. The EMA however limited the use of Eviplera only in patients with low viral load (below 100,000 HIV RNA copies/mL). Complera/ Eviplera is the second STR approved in the EU for the treatment of HIV, the first being Atripla, which is marketed by Gilead and Bristol Myers Squibb (BMY). Gilead has a license and collaboration agreement with Tibotec Pharmaceuticals ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Earnings Grow With HIV Franchise</title>
		<link>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025</link>
		<comments>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:46:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80025</guid>
		<description><![CDATA[Gilead Sciences Inc.’s (GILD) adjusted earnings per share of 95 cents for the second quarter of 2011 were 14 cents above the year-earlier earnings of 81 cents. The earnings growth was driven by a solid top-line performance in the reported quarter. Earnings were however a penny short of the Zacks Consensus Estimate. Second quarter revenues were up 11% from the prior-year quarter to $2.14 billion. Total revenues also topped the Zacks Consensus Estimate of $2.10 billion. Revenue performance was driven by a robust performance of the antiviral (HIV) and cardiovascular franchises. The Second Quarter in Detail Product sales, at $2.04 billion, were up 13% over the prior year due to a strong performance of antiviral products. Gilead’s product sales crossed the $2 billion mark for the first time in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Gets HIV Rights from Gilead</title>
		<link>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031</link>
		<comments>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:42:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79031</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access to HIV therapies in developing nations. The therapies include elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral (ARV) boosting agent; and the &#8220;Quad,&#8221; a once-daily combination pill of elvitegravir, cobicistat and Gilead’s another HIV combination medicine Truvada (Emtriva+Viread). The rights are an extension of the non-exclusive license granted to Matrix to produce and sell active pharmaceutical ingredients and finished products, including generic versions of Viread and Truvada in 95 developing countries including India. The license has now been expanded to include 16 additional countries, the three investigational medicines and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences /Johnson &amp; Johnson to Make HIV Combo Drug</title>
		<link>http://www.stockbloghub.com/2011/06/30/gild-gilead-sciences-johnson-johnson-to-make-hiv-combo-drug/78063</link>
		<comments>http://www.stockbloghub.com/2011/06/30/gild-gilead-sciences-johnson-johnson-to-make-hiv-combo-drug/78063#comments</comments>
		<pubDate>Thu, 30 Jun 2011 20:42:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78063</guid>
		<description><![CDATA[Gilead Sciences, Inc.’s (GILD) strong HIV franchise received yet another shot in the arm with the announcement of a license agreement with Tibotec Pharmaceuticals, a division of Johnson &#38; Johnson (JNJ), to develop and commercialize a new fixed dose combination HIV drug. The combination drug will bring together Gilead’s pipeline candidate cobicistat and Tibotec&#8217;s protease inhibitor Prezista (darunavir). Cobicistat is being developed by Gilead in late stage trials as a booster for protease inhibitors in the treatment of HIV. Gilead is developing cobicistat, both as a stand-alone product and for use in combination with other agents. Prezista is marketed in the US by Johnson &#38; Johnson for the treatment of HIV in combination with ritonavir (standard of care) and other antiretroviral agents. Under the agreement, Tibotec will be responsible for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/gild-gilead-sciences-johnson-johnson-to-make-hiv-combo-drug/78063/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek</title>
		<link>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386</link>
		<comments>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386#comments</comments>
		<pubDate>Fri, 24 Jun 2011 20:36:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77386</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England Journal of Medicine. The trial results demonstrated that when patients suffering from chronic hepatitis C (HCV) were given Incivek combination therapy, they experienced significant improvement in sustained viral response (SVR) rates, as compared to those who received pegylated-interferon and ribavirin alone. In the ADVANCE study, Incivek combination therapy demonstrated the aforesaid results in new patients, while the REALIZE study consisted of treatment-failed patients. We note that in the ADVANCE study, majority of the patients treated with Incivek combination therapy completed the treatment in 24 weeks, which is half the time needed in the pegylated-interferon and ribavirin arm. Further, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs First Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667</link>
		<comments>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667#comments</comments>
		<pubDate>Mon, 18 Apr 2011 14:31:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71667</guid>
		<description><![CDATA[Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1%. Abbott Labs has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter average of 1.0%. Fourth Quarter 2010 Recap Abbott Laboratories reported fourth quarter earnings of $1.30 per share, a penny above the Zacks Consensus Estimate. Earnings increased 10.2% from the year-ago period. Higher revenues helped drive results. However, including one-time items, earnings declined 6.1% to $0.92 per share. Fourth quarter revenues increased 13.4% to $9.97 billion, above the Zacks Consensus Estimate of $9.89 billion. (Read our full coverage on the earnings report at Abbott Labs Tops ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Earns European Clearance for Baraclude</title>
		<link>http://www.stockbloghub.com/2011/03/16/bmy-bristol-myers-squibb-earns-european-clearance-for-baraclude/67935</link>
		<comments>http://www.stockbloghub.com/2011/03/16/bmy-bristol-myers-squibb-earns-european-clearance-for-baraclude/67935#comments</comments>
		<pubDate>Wed, 16 Mar 2011 16:11:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67935</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) received a boost with the European Commission (EC) approving Baraclude (entecavir) for an additional indication. The current approval by the European regulatory authorities allows Bristol-Myers to market Baraclude in 27 nations of the European Union for treating adults suffering from chronic hepatitis B (CHB) with decompensated liver disease. The US clearance for Baraclude for the same indication came in October 2010. Decompensated liver disease leads to improper functioning of the liver due to severe scarring of the organ and often needing liver transplantation. Approximately, 350 million people are infected by the CHB virus across the globe. The European approval for the additional indication was based on encouraging safety and efficacy data from a randomised, open-label, multi-centre study (ETV-048) study. Data from the study revealed that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/16/bmy-bristol-myers-squibb-earns-european-clearance-for-baraclude/67935/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Refiles FDA New Drug Application for HIV Combo Pill</title>
		<link>http://www.stockbloghub.com/2011/02/14/gild-gilead-sciences-refiles-fda-new-drug-application-for-hiv-combo-pill/66902</link>
		<comments>http://www.stockbloghub.com/2011/02/14/gild-gilead-sciences-refiles-fda-new-drug-application-for-hiv-combo-pill/66902#comments</comments>
		<pubDate>Tue, 15 Feb 2011 00:29:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66902</guid>
		<description><![CDATA[Gilead Sciences Inc. (GILD) recently refiled a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for the single-tablet combination of Truvada and TMC-278 (rilpivirine). The company is seeking to get the combination drug approved as a treatment of adult HIV patients. Gilead&#8217;s Truvada is a fixed-dose combination of Viread and Emtriva, marketed as a treatment for HIV, while Johnson &#38; Johnson&#8216;s (JNJ) TMC-278 is a non-nucleoside reverse transcriptase inhibitor. Johnson &#38; Johnson is currently seeking US and European approval for TMC-278 for the treatment of HIV in adults. Gilead first filed for the approval of the combination pill in November 2010. However, on January 25, 2011, the FDA issued a refuse-to-file notice for the company&#8217;s NDA for the once daily, single tablet, fixed dose combination of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/14/gild-gilead-sciences-refiles-fda-new-drug-application-for-hiv-combo-pill/66902/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Terminates Letairis Phase III Trial</title>
		<link>http://www.stockbloghub.com/2010/12/24/gild-gilead-sciences-terminates-letairis-phase-iii-trial/63567</link>
		<comments>http://www.stockbloghub.com/2010/12/24/gild-gilead-sciences-terminates-letairis-phase-iii-trial/63567#comments</comments>
		<pubDate>Fri, 24 Dec 2010 20:10:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[United Therapeutics Corporation]]></category>
		<category><![CDATA[UTHR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63567</guid>
		<description><![CDATA[Gilead Sciences Inc.(GILD) recently announced that it will terminate its phase III trial (ARTEMIS-IPF) studying Letairis (ambrisentan) for the treatment of idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. The study’s Data Monitoring Committee (DMC) had conducted an interim analysis of the efficacy and safety data of the trial. The data was also reviewed by Gilead. It did not show any treatment benefit in the patients receiving Letairis. Gilead is currently conducting a thorough analysis of the data and will present the results of the analysis once they are available. Letairis, currently marketed for the treatment of pulmonary arterial hypertension (PAH), competes with drugs like Actelion Pharmaceuticals’  Tracleer (bosentan) United Therapeutics’ (UTHR) Tyvaso and Adcirca and Pfizer’s (PFE) Revatio. Letairis is not the key revenue generator for Gilead and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/24/gild-gilead-sciences-terminates-letairis-phase-iii-trial/63567/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Earns FDA Label Expansion</title>
		<link>http://www.stockbloghub.com/2010/11/17/bmy-bristol-myers-squibb-earns-fda-label-expansion/55719</link>
		<comments>http://www.stockbloghub.com/2010/11/17/bmy-bristol-myers-squibb-earns-fda-label-expansion/55719#comments</comments>
		<pubDate>Thu, 18 Nov 2010 04:58:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55719</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Co. (BMY) received a boost with the US Food and Drug Administration (FDA) approving Baraclude (entecavir) for an additional indication. The current approval by the US regulatory authorities allows Bristol-Myers to market Baraclude for treating a more serious form of liver disease than hepatitis B virus (HBV), for which it is one of the top prescribed therapies. The latest approval allows Baraclude to be marketed for treating adults suffering from chronic hepatitis B (CHB) with decompensated liver disease. The disease leads to improper functioning of the liver due to severe scarring of the organ. Chronic hepatitis B infection, which affects approximately 1.25 million Americans, is often linked with inflammation of the liver. The FDA approval for the additional indication is based on encouraging safety and efficacy data ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/bmy-bristol-myers-squibb-earns-fda-label-expansion/55719/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Third Quarter 2010 Earnings Above Estimates on Antiviral Franchise</title>
		<link>http://www.stockbloghub.com/2010/11/17/gild-gilead-sciences-third-quarter-2010-earnings-above-estimates-on-antiviral-franchise/55975</link>
		<comments>http://www.stockbloghub.com/2010/11/17/gild-gilead-sciences-third-quarter-2010-earnings-above-estimates-on-antiviral-franchise/55975#comments</comments>
		<pubDate>Thu, 18 Nov 2010 04:49:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55975</guid>
		<description><![CDATA[Gilead Sciences’ (GILD) third quarter 2010 earnings of $0.85 (excluding special items but including stock-based compensation expense) was a penny above the Zacks Consensus Estimate and well above the year-ago earnings of $0.74. The improved showing in the reported quarter was mainly attributable to strong sales of antiviral products. Revenues climbed 8% to $1.94 billion, marginally above the Zacks Consensus Revenue Estimate of $1.93 billion. Foreign exchange (Fx) fluctuations adversely impacted revenues by $44.2 million. Revenues Product sales climbed 13% to $1.87 billion driven by sales growth of antiviral products such as Atripla (up 23% to $742.7 million), Truvada (up 8% to $668.7 million) and Viread (up 9% to $184.3 million). Antiviral product sales for the quarter grew 12% to $1.65 billion. While the US market contributed $922.6 million (up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/gild-gilead-sciences-third-quarter-2010-earnings-above-estimates-on-antiviral-franchise/55975/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Reports Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/10/29/vrtx-vertex-pharmaceuticals-reports-wider-loss/57047</link>
		<comments>http://www.stockbloghub.com/2010/10/29/vrtx-vertex-pharmaceuticals-reports-wider-loss/57047#comments</comments>
		<pubDate>Fri, 29 Oct 2010 16:06:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57047</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted a higher third-quarter loss (including stock-based compensation expense) of 99 cents per share, compared with the Zacks Consensus Estimate of a loss of 91 cents and the year-ago loss of 83 cents. Increased expenses related to the potential launch of telaprevir (being developed for the treatment of hepatitis C virus or HCV) led to the decline. Quarter in Detail Quarterly revenues amounted to $23.8 million, lower than the Zacks Consensus Estimate of $31 million and the year-ago figure of $25 million. Vertex Pharma’s revenues consist of royalty revenues (up 4% to $8.2 million) and collaborative revenues (down 9% to $15.6 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenues consist of reimbursements received by Vertex ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/29/vrtx-vertex-pharmaceuticals-reports-wider-loss/57047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Files Marketing Authorization Application for HIV Drug</title>
		<link>http://www.stockbloghub.com/2010/09/08/gild-gilead-sciences-files-marketing-authorization-application-for-hiv-drug/50720</link>
		<comments>http://www.stockbloghub.com/2010/09/08/gild-gilead-sciences-files-marketing-authorization-application-for-hiv-drug/50720#comments</comments>
		<pubDate>Wed, 08 Sep 2010 18:19:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50720</guid>
		<description><![CDATA[Gilead Sciences Inc. (GILD) recently announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for its once daily, single tablet, fixed dose combination of Truvada and TMC278 (rilpivirine) as a HIV treatment for adult patients. The MAA will first be reviewed by the Committee for Medicinal Products for Human Use (CHMP) and, based on the CHMP’s opinion, the EMA will deliver its decision regarding the approval of the drug. Truvada is a fixed dose, once daily tablet containing Viread and Emtriva, both manufactured by Gilead, and marketed for the treatment of HIV, while TMC278 is being developed by Tibotec Pharmaceuticals, which is a subsidiary of Johnson &#38; Johnson (JNJ), for treatment-naïve HIV infected adults. Gilead entered into an agreement with Tibotec ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/08/gild-gilead-sciences-files-marketing-authorization-application-for-hiv-drug/50720/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Neutral Rating Due To Generic Risk For Hepsera</title>
		<link>http://www.stockbloghub.com/2010/08/22/gild-gilead-sciences-neutral-rating-due-to-generic-risk-for-hepsera/48712</link>
		<comments>http://www.stockbloghub.com/2010/08/22/gild-gilead-sciences-neutral-rating-due-to-generic-risk-for-hepsera/48712#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:22:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48712</guid>
		<description><![CDATA[Gilead Sciences Inc. (GILD) recently announced that Sigmapharm Laboratories, LLC is seeking to manufacture and market a generic version of Gilead&#8217;s hepatitis B (HBV) treatment, Hepsera. Sigmapharm Labs submitted an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for the same. Gilead is currently reviewing the letter. We expect the company to file a patent infringement suit against Sigmapharm Labs within 45 days. This should prevent the regulatory body from granting final approval to the generic manufacturer for 30 months or until a district court rules against Gilead&#8217;s patent, whichever occurs earlier. Although Hepsera made up 4% of total revenues of fiscal 2009, we do not expect the generic filing for the drug to have any major negative impact on total revenues. Sales for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/gild-gilead-sciences-neutral-rating-due-to-generic-risk-for-hepsera/48712/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UTHR) United Therapeutics Beats Expectations on Strong Revenues</title>
		<link>http://www.stockbloghub.com/2010/05/06/uthr-united-therapeutics-beats-expectations-on-strong-revenues/36477</link>
		<comments>http://www.stockbloghub.com/2010/05/06/uthr-united-therapeutics-beats-expectations-on-strong-revenues/36477#comments</comments>
		<pubDate>Thu, 06 May 2010 23:20:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[United Therapeutics Corporation]]></category>
		<category><![CDATA[UTHR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36477</guid>
		<description><![CDATA[United Therapeutics Corp. (UTHR) reported first-quarter profit of 32 cents per share, a couple of cents above the Zacks Consensus Estimate and 28% above the year-ago earnings of 25 cents. A huge boost in revenues helped drive earnings despite an increase in operating expenses. Revenues increased 61.6% to $128.9 million in the reported quarter, primarily due to the continued increase in the number of patients being prescribed Remodulin and contributions from new products, Tyvaso and Adcirca. Net product sales, consisting of Remodulin, Tyvaso and Adcirca sales Incorporatedreased 63.5% to $125.7 million in the reported quarter. United Therapeutics derives the majority of its product revenues from Remodulin, which posted sales of $95.8 million, up 24.7%. Meanwhile, newly launched products, Tyvaso and Adcirca, contributed $24.9 million and $5 million, respectively to first ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/06/uthr-united-therapeutics-beats-expectations-on-strong-revenues/36477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Beats The Street but Lowers Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/21/gild-gilead-sciences-beats-the-street-but-lowers-outlook/34484</link>
		<comments>http://www.stockbloghub.com/2010/04/21/gild-gilead-sciences-beats-the-street-but-lowers-outlook/34484#comments</comments>
		<pubDate>Wed, 21 Apr 2010 22:18:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34484</guid>
		<description><![CDATA[Gilead Sciences (GILD) reported strong first quarter fiscal 2010 results with revenues increasing 36% year-over-year to $2.09 billion. The company’s earnings per share (EPS) came in at 92 cents. However, excluding non- recurring items and treating stock-based compensation as a regular expense, the company’s EPS of 95 cents surpassed the Zacks Consensus Estimate of 91 cents and the year-ago period’s 63 cents. Revenues Gilead’s robust growth was driven by strong product sales, especially the antiviral franchise. Product sales increased 24% to $1.79 billion driven by growth in sales of antiviral products such as Atripla (growth of 36% to $692.9 million), Truvada (growth of 11% to $657.8 million) and Viread (growth of 13% to $180.7 million). Healthcare reform impacted product sales by $29.4 million during the quarter. Antiviral product sales for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/gild-gilead-sciences-beats-the-street-but-lowers-outlook/34484/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Earnings Preview &#8211; Fourth Quarter Highlights</title>
		<link>http://www.stockbloghub.com/2010/04/14/gild-gilead-sciences-earnings-preview-fourth-quarter-highlights/33712</link>
		<comments>http://www.stockbloghub.com/2010/04/14/gild-gilead-sciences-earnings-preview-fourth-quarter-highlights/33712#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:49:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33712</guid>
		<description><![CDATA[Gilead Sciences (GILD) is scheduled to release its first quarter 2010 earnings on Apr 20, 2010. The company is expected to earn 96 cents during the quarter, according to the Zacks Consensus Estimate. Fourth quarter highlights Gilead reported revenue of $2.03 billion, up 42%, compared to the year-ago period and earnings of 90 cents per share (excluding non- recurring items) surpassing the Zacks Consensus Estimate by 8 cents. The robust growth was driven by strong product sales, especially the antiviral franchise. The company expects to generate sales of $7.6-$7.7 billion for the full year, an increase of 17% &#8211; 19% over 2009. Atripla, with quarterly sales of $697.8 million became the lead product surpassing Truvada ($670.7 million) for the first time. Moreover, Gilead’s royalty, contract and other revenues increased based ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/gild-gilead-sciences-earnings-preview-fourth-quarter-highlights/33712/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Initiates Late-Stage Trial</title>
		<link>http://www.stockbloghub.com/2010/04/13/gild-gilead-sciences-initiates-late-stage-trial/33650</link>
		<comments>http://www.stockbloghub.com/2010/04/13/gild-gilead-sciences-initiates-late-stage-trial/33650#comments</comments>
		<pubDate>Tue, 13 Apr 2010 21:59:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33650</guid>
		<description><![CDATA[Recently, Gilead Sciences (GILD) initiated the phase III program of Quad, which is a fixed dose combination of four drugs: elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The phase III program consists of two trials (Studies 102 and 103), which will compare Quad with a standard HIV therapy in treatment-naïve patients. In addition, Gilead is examining the efficacy of cobicistat as a boosting agent for other antiretrovirals. The company also plans to initiate a phase III trial to evaluate the impact of cobicistat-boosted atazanavir as against ritonavir-boosted atazanavir, both in combination with Truvada (emtricitabine and tenofovir disoproxil fumarate). In the phase II trial, it was observed that after 24 weeks, about 90% of the patients in the Quad arm experienced a reduction in the viral load factor (less than 50 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/13/gild-gilead-sciences-initiates-late-stage-trial/33650/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Shows Uptrend in Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/05/gild-gilead-sciences-shows-uptrend-in-earnings-estimates/29864</link>
		<comments>http://www.stockbloghub.com/2010/03/05/gild-gilead-sciences-shows-uptrend-in-earnings-estimates/29864#comments</comments>
		<pubDate>Fri, 05 Mar 2010 18:40:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29864</guid>
		<description><![CDATA[Earnings estimates for Gilead Sciences (GILD) are on the rise following the release of strong fourth quarter and full year 2009 results. The company’s earnings per share (EPS) came in at 90 cents, well above the Zacks Consensus Estimate of 82 cents and the year ago quarter’s earnings of 59 cents. Full-year earnings increased 41% to $2.91. For the full year, Gilead reported a 31% increase in revenues to $7.01 billion primarily driven by strong growth in its antiviral franchise. Product sales for 2009 increased 27% to $6.47 billion led by the growth in sales of antiviral products such as Atripla (up 51% to $2.4 billion), Truvada (up 18% to $2.5 billion) and Viread (up 7% to $667.5 million). Antiviral product sales for 2009 grew to $5.84 billion, up 25%. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/05/gild-gilead-sciences-shows-uptrend-in-earnings-estimates/29864/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Earns FDA Approval for Cayston Drug</title>
		<link>http://www.stockbloghub.com/2010/03/01/gild-gilead-sciences-earns-fda-approval-for-cayston-drug/29387</link>
		<comments>http://www.stockbloghub.com/2010/03/01/gild-gilead-sciences-earns-fda-approval-for-cayston-drug/29387#comments</comments>
		<pubDate>Mon, 01 Mar 2010 23:17:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29387</guid>
		<description><![CDATA[In a positive development, Gilead Sciences (GILD) received long-awaited US Food and Drug Administration (FDA) approval for Cayston (aztreonam for inhalation solution). The drug is indicated for the treatment of lung infection caused by Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF). Cayston, to be administered in dosages of 75 mg thrice daily over a 28-day period through the Altera Nebulizer System, will be available in the U.S. shortly at certain specialty pharmacies. The approval does not surprise us, since Cayston received a positive opinion from the FDA’s Anti-Infective Drugs Advisory Committee in Dec. 2009. Although the New Drug Application (NDA) had been submitted in Nov. 2007, there were several hiccups in the approval process. In Sep. 2008, Cayston was denied approval by the FDA, which asked Gilead to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/01/gild-gilead-sciences-earns-fda-approval-for-cayston-drug/29387/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences &#8211; Earnings Report Posts Record-Setting Quarter</title>
		<link>http://www.stockbloghub.com/2010/02/05/gild-gilead-sciences-earnings-report-posts-record-setting-quarter/27139</link>
		<comments>http://www.stockbloghub.com/2010/02/05/gild-gilead-sciences-earnings-report-posts-record-setting-quarter/27139#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:36:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27139</guid>
		<description><![CDATA[Gilead Sciences, Inc (GILD) posted record sales last week and analysts continue to raise estimates. The double-digit growth rates are also coming at a great value. Company Description Gilead Sciences is a pharmaceutical company that makes new medicines for life-threatening diseases. Record-Setting Quarter On Jan 26 Gilead reported fourth-quarter results that included record sales of $1.8 billion, a 30% increase. Revenues came in just over $2 billion. This was a 42% increase and led to net income of $802 million, up from $560 million. Earnings per shares were 90 cents, topping the Zacks Consensus Estimate by 8 cents. This was the sixth consecutive earnings surprise. Buying Back A few days after the earnings release, Gilead announced that it will repurchase up to $1 billion in its common stock. The program ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/gild-gilead-sciences-earnings-report-posts-record-setting-quarter/27139/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2010/02/05/gild-gilead-sciences-bull-of-the-day/27143</link>
		<comments>http://www.stockbloghub.com/2010/02/05/gild-gilead-sciences-bull-of-the-day/27143#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:18:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27143</guid>
		<description><![CDATA[Gilead Sciences (GILD) reported another strong quarter with earnings per share coming in at $0.90, well above the Zacks Consensus Estimate of $0.82 and the year-ago quarter&#8217;s earnings of $0.59. For the full year, the company reported a 31% growth in revenues. We remain optimistic about growth of HIV/AIDS franchise drugs Truvada and Atripla. Earnings over the past few quarters have consistently been above expectations, specifically on strong sales of the HIV franchise products. Meanwhile, the worldwide panic regarding swine-flu boosted the reported quarter&#8217;s royalty income, a trend we expect to continue, thanks to increased sales of the anti-viral drug Tamiflu. Given these factors, we upgrade the stock to Outperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/gild-gilead-sciences-bull-of-the-day/27143/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Pharma &amp; Biotech Stock Review &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385</link>
		<comments>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385#comments</comments>
		<pubDate>Sat, 30 Jan 2010 00:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26385</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/29/rx-pharma-biotech-stock-review-industry-outlook/26385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences&#8217; Reports Results 42% Ahead of Last Year</title>
		<link>http://www.stockbloghub.com/2010/01/27/gild-gilead-sciences-reports-results-42-ahead-of-last-year/26134</link>
		<comments>http://www.stockbloghub.com/2010/01/27/gild-gilead-sciences-reports-results-42-ahead-of-last-year/26134#comments</comments>
		<pubDate>Wed, 27 Jan 2010 18:37:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26134</guid>
		<description><![CDATA[Gilead Sciences (GILD) has reported a strong fourth quarter and full year results. The company reported quarterly revenues of $2.03 billion, up 42% compared to the year-ago period. Gilead’s earnings per share (EPS) came in at 87 cents. However, excluding non- recurring items, the company’s EPS of 90 cents surpassed the Zacks Consensus Estimate of 82 cents and the year-ago period’s 59 cents. For the full year of 2009, Gilead reported a 31% increase in revenues to $7.01 billion and EPS (excluding non recurring items) of $2.91 compared to $2.07. Gilead’s robust growth was driven by strong product sales, especially the antiviral franchise. Product sales for 2009 increased 27% to $6.47 billion driven by growth in sales of antiviral products such as Atripla (growth of 51% to $2.4 billion), Truvada ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/gild-gilead-sciences-reports-results-42-ahead-of-last-year/26134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Sees Setback With One of its Pipeline Drugs</title>
		<link>http://www.stockbloghub.com/2010/01/21/mrk-merck-sees-setback-with-one-of-its-pipeline-drugs/25623</link>
		<comments>http://www.stockbloghub.com/2010/01/21/mrk-merck-sees-setback-with-one-of-its-pipeline-drugs/25623#comments</comments>
		<pubDate>Thu, 21 Jan 2010 19:13:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25623</guid>
		<description><![CDATA[Merck (MRK) received a setback recently with respect to one of its pipeline candidates, vicriviroc. The drug did not meet the primary efficacy endpoint in two late stage studies (phase III) with HIV patients who have already been treated with other medication. Following this, Merck has shelved its plan to seek marketing approval for the drug. Earlier, results from a mid-stage trial of vicriviroc in treatment-experienced patients found that the drug was being well tolerated and was effective during the two years of therapy. Merck will continue phase II studies of the drug in treatment-naïve HIV patients, for which patient enrollment is complete. We had high hopes of vicriviroc, which became a part of Merck’s portfolio following its merger with Schering-Plough. Merck’s other HIV drug Isentress (raltegravir) is approved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/21/mrk-merck-sees-setback-with-one-of-its-pipeline-drugs/25623/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($JPM) JP Morgan Healthcare Conference in San Francisco</title>
		<link>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897</link>
		<comments>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897#comments</comments>
		<pubDate>Wed, 13 Jan 2010 23:58:21 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[WBMD]]></category>
		<category><![CDATA[WebMD Health Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24897</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 13, 2010: Issue #1174 Cautiously optimistic. Very cautiously optimistic. That’s how I’d describe the overall mood at this year’s JP Morgan Healthcare Conference in San Francisco. While folks are certainly in a better frame of mind than this time last year (when it seemed like we were in the middle of financial Armageddon), they’re still a bit gun-shy. But with the huge stock market rally and partnership/financing deals available again, the tone is more upbeat. As one banker said, “money is flowing into the market again.” These days, the conference is a major event and has become increasingly difficult to get into. Luckily, I’ve got the right credentials to get inside (without having to resort to a White House-style gatecrash) and give you ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Suffers Stage III Setback</title>
		<link>http://www.stockbloghub.com/2009/12/28/gild-gilead-sciences-suffers-stage-iii-setback/23750</link>
		<comments>http://www.stockbloghub.com/2009/12/28/gild-gilead-sciences-suffers-stage-iii-setback/23750#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:31:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23750</guid>
		<description><![CDATA[Gilead Sciences (GILD) received a major pipeline setback with disappointing results from a phase III trial of darusentan in which it failed to achieve its primary endpoint. The drug was being studied under an international clinical trial (DAR-312) for the treatment of resistant hypertension. As a result of the setback, Gilead is considering the option of dropping the program so that its resources can be utilized for other potential candidates rather than conducting another intensive phase III study. The DAR-312 trial was conducted with 849 patients who were randomized to receive darusentan (in three dosage forms of 50, 100 or 300 mg once daily), an active comparator (guanfacine 1 mg once daily) or placebo. The drug was being studied for its effectiveness to improve systolic and diastolic blood pressure compared ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/gild-gilead-sciences-suffers-stage-iii-setback/23750/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Closer to FDA Approval</title>
		<link>http://www.stockbloghub.com/2009/12/11/gild-gilead-sciences-closer-to-fda-approval/22620</link>
		<comments>http://www.stockbloghub.com/2009/12/11/gild-gilead-sciences-closer-to-fda-approval/22620#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:49:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22620</guid>
		<description><![CDATA[Gilead Sciences, Inc (GILD) received a positive opinion from the Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration (FDA). Gilead is seeking FDA approval for inhalable aztreonam for the treatment of lung infection caused by Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF). While the committee voted 15-2 with respect to the drug’s safety and efficacy, there was a unanimous opinion regarding the dosage (75 mg three times daily). Although the FDA is not bound to follow the committee’s decision, it generally does so. Gilead has been assigned a Prescription Drug User Fee Act (PDUFA) date of Feb 13, 2010. Currently, the drug is being made available to the patients in the US under the FDA’s Expanded Access Program. The New Drug Application (NDA) for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/gild-gilead-sciences-closer-to-fda-approval/22620/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences-GlaxoSmithKline Deal Targets Asia</title>
		<link>http://www.stockbloghub.com/2009/12/03/gild-gilead-sciences-glaxosmithkline-deal-targets-asia/21852</link>
		<comments>http://www.stockbloghub.com/2009/12/03/gild-gilead-sciences-glaxosmithkline-deal-targets-asia/21852#comments</comments>
		<pubDate>Thu, 03 Dec 2009 22:50:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21852</guid>
		<description><![CDATA[Recently, Gilead Sciences (GILD) entered into a licensing agreement with GlaxoSmithKline (GSK) to commercialize Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection in adults in five Asian countries. As per the deal, while Gilead will retain exclusive commercialization rights for the compound in Hong Kong, Singapore, South Korea and Taiwan, Glaxo will market the drug in China. Both companies have agreed to pay royalties to their counterpart for sales of the drug in their respective market. The companies are trying to tap the Asian market given the high prevalence of HBV in this area. In future, the scope of the agreement may be extended to Japan and other countries as well. Moreover, this deal will strengthen Glaxo’s portfolio further in the emerging markets. Viread ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/03/gild-gilead-sciences-glaxosmithkline-deal-targets-asia/21852/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Awaits Committee Outcome</title>
		<link>http://www.stockbloghub.com/2009/11/14/gild-gilead-sciences-awaits-committee-outcome/20491</link>
		<comments>http://www.stockbloghub.com/2009/11/14/gild-gilead-sciences-awaits-committee-outcome/20491#comments</comments>
		<pubDate>Sat, 14 Nov 2009 23:37:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20491</guid>
		<description><![CDATA[Gilead Sciences, Inc (GILD) is awaiting the outcome of the Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration (FDA) scheduled on December 10, 2009. The committee will review Gilead ’s aztreonam for inhalation solution, an investigational product for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF). Earlier, in September 2008, the drug was denied approval by the FDA, which then asked Gilead to resubmit the application with more data. In September 2009, the drug received conditional marketing approval in Canada and Europe under the trade name Cayston (aztreonam lysine 75 mg powder and solvent for nebuliser solution). Gilead plans to make the product available in Germany and the UK in early 2010. Aztreonam formulated with lysine is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/gild-gilead-sciences-awaits-committee-outcome/20491/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Top Franklin Templeton Funds &#8211; Mutual Fund Education</title>
		<link>http://www.stockbloghub.com/2009/11/11/gild-top-franklin-templeton-funds-mutual-fund-education-2/20266</link>
		<comments>http://www.stockbloghub.com/2009/11/11/gild-top-franklin-templeton-funds-mutual-fund-education-2/20266#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:39:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20266</guid>
		<description><![CDATA[Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms. This non-diversified fund may invest a substantial portion of assets in equity securities of smaller capitalization companies with a market capitalization of less than $1.5 billion. Gilead Sciences Inc. (GILD), Celgene Corp. (CELG) and Genzyme Corp. (GENZ) are among the fund’s key holdings. Templeton Developing Markets A (TEDMX) seeks long-term capital appreciation through investment in securities of emerging economies. The fund may invest up to 20% of net assets in the securities of issuers in developed market countries. It may also invest in exchange-traded funds to gain exposure to certain segments of the equity markets while maintaining liquidity. J. Mark Mobius has been lead manager at the fund since October ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/gild-top-franklin-templeton-funds-mutual-fund-education-2/20266/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RX) Big Pharma and Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146</link>
		<comments>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:57:38 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMS Health Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RX]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/rx-big-pharma-and-biotech-industry-outlook/20146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UTHR) United Therapeutics Corporation Misses Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/02/uthr-united-therapeutics-corporation-misses-earnings-estimates/19476</link>
		<comments>http://www.stockbloghub.com/2009/11/02/uthr-united-therapeutics-corporation-misses-earnings-estimates/19476#comments</comments>
		<pubDate>Tue, 03 Nov 2009 04:43:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[United Therapeutics Corporation]]></category>
		<category><![CDATA[UTHR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19476</guid>
		<description><![CDATA[United Therapeutics Corporation (UTHR) reported a net income of 21 cents per share in the third quarter, well below the Zacks Consensus Estimate of 31 cents. The company reported earnings of 22 cents in the year-ago period. Even though revenues increased 29.6% to $97.2 million in the reported quarter, higher operating expenses led to the lower than expected net income. The increase in revenues was primarily due to the continued increase in the number of patients being prescribed Remodulin and the recent launches of new products, Tyvaso and Adcirca. Net product sales, consisting of Remodulin, Tyvaso and Adcirca sales Incorporatedreased 30.4% to $94.1 million. The company derives the majority of its product revenues from Remodulin, which posted sales of $87.4 million, up 21.3%. Meanwhile, newly launched products, Tyvaso and Adcirca, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/02/uthr-united-therapeutics-corporation-misses-earnings-estimates/19476/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Presented Positive Data From Two Phase III Clinical Trials</title>
		<link>http://www.stockbloghub.com/2009/11/02/gild-gilead-sciences-presented-positive-data-from-two-phase-iii-clinical-trials/19417</link>
		<comments>http://www.stockbloghub.com/2009/11/02/gild-gilead-sciences-presented-positive-data-from-two-phase-iii-clinical-trials/19417#comments</comments>
		<pubDate>Mon, 02 Nov 2009 21:54:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19417</guid>
		<description><![CDATA[Gilead Sciences Inc. (GILD) recently presented positive data from a 3 year (144-week) open label two pivotal phase III clinical trials – Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. The company will present this data at the upcoming annual meeting of the American Association for the Study of Liver Diseases in Boston this week. The drug was approved by the US Food and Drug Administration for chronic hepatitis B in adults in 2008. It was observed that 87% and 71% patients of the two study groups, study 102 and 103, respectively, experienced sustained suppression of HBV DNA levels in the blood (below 400 copies/mL) after receiving Viread for up to 144 weeks. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/02/gild-gilead-sciences-presented-positive-data-from-two-phase-iii-clinical-trials/19417/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences&#8217; Strong Performance</title>
		<link>http://www.stockbloghub.com/2009/10/21/gild-gilead-sciences-strong-performance/18388</link>
		<comments>http://www.stockbloghub.com/2009/10/21/gild-gilead-sciences-strong-performance/18388#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:42:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18388</guid>
		<description><![CDATA[Gilead Sciences (GILD) posted strong third quarter results yesterday. The company’s earnings per share of 74 cents was well above the Zacks Consensus Estimate of 69 cents and last year’s profit of 52 cents. Gilead reported $1.8 billion of revenues during the quarter, an increase of 31% compared to $1.37 billion in the prior-year period of 2008 on strong product sales, especially of the antiviral franchise. Revenues were hampered by a $51 million of unfavorable foreign exchange movement. Product sales increased 23% to $1.65 billion driven by the year-over-year growth in sales of antiviral products such as Atripla (growth of 42% to $605.3 million), Truvada (growth of 13% to $620.6 million), Viread (growth of 9% to $156 million) and the inclusion of Ranexa in the portfolio, following the $1.4 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/gild-gilead-sciences-strong-performance/18388/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Beast Estimates and Raises Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/14/jnj-johnson-johnson-beast-estimates-and-raises-guidance/17570</link>
		<comments>http://www.stockbloghub.com/2009/10/14/jnj-johnson-johnson-beast-estimates-and-raises-guidance/17570#comments</comments>
		<pubDate>Wed, 14 Oct 2009 16:37:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17570</guid>
		<description><![CDATA[Johnson &#38; Johnson’s (JNJ) third quarter earnings of $1.20 surpassed the Zacks Consensus Estimate by 7 cents and by 3 cents from the year-ago period. However, the company reported revenues of $15.1 billion, a decline of 5.3% compared to the third quarter of 2008. While 2.8% of the decline in revenue was due to operational factors, foreign exchange movement was responsible for the remaining 2.5% decline. Sales in both domestic and international markets recorded declines of 8.1% and 2.5%, respectively. Johnson &#38; Johnson’s diversified business model is helping the company pave its way through tough situations. For the second quarter in a row, the company’s medical devices segment posted higher revenues than the pharmaceuticals. While medical devices recorded an increase of 2.3% compared to the year-ago period, consumer products and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/jnj-johnson-johnson-beast-estimates-and-raises-guidance/17570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

